The development of gene expression signatures since the early 2000′s offered standardized assays to evaluate the risk of recurrence for women with HR-positive/HER2-negative (HR+/HER2−) early breast cancer, and therefore helped to individualize the treatment decisions. The gene discussed is ERBB2; the disease is breast cancer.